e ungeted suppressats that only have an effects on the immune cells causing issues in the joints. There are two main cat

[answerhappygod]

E Ungeted Suppressats That Only Have An Effects On The Immune Cells Causing Issues In The Joints There Are Two Main Cat 1 (49.4 KiB) Viewed 22 times

E Ungeted Suppressats That Only Have An Effects On The Immune Cells Causing Issues In The Joints There Are Two Main Cat 2 (41.09 KiB) Viewed 22 times

e ungeted suppressats that only have an effects on the immune cells causing issues in the joints. There are two main categories of DMARDS, non-biologic and biologic. What is 1 pts a main difference between these two categories of DMARDS? O Biologic DMARDS target the COX-2 pathway in a similar way to NSAIDs, whilst non-biologic DMARDs that target specific immune cells for destruction. O Non-biologic DMARDS tend to suppress general cytokine activation and immune cell chemotaxis, whilst biologic DMARDS target specific cytokines or cells of the immune system to reduce inflammation in the joints. O Both types of DMARDS work by destroying all immune cells to suppress the immune system and stop progression of RA. O Non-biologic DMARDS target the COX-2 pathway activation (in a different way to NSAIDs), whilst biologic DMARDS target Lipooxygenase pathway activation. 1 pts Why would you suggest trying a non-biologic DMARD like Methotrexate or Sulfasalazine for treatment of RA before a biologic DMARD like Rituximab? Because non-biologic DMARDs have so few side effects they are not only effective but much safer than
PODAygenase pathway activation. 1 pts Why would you suggest trying a non-biologic DMARD like Methotrexate or Sulfasalazine for treatment of RA before a biologic DMARD like Rituximab? O Because non-biologic DMARDS have so few side effects they are not only effective but much safer than biologics. O Because biologic DMARDS are newer they are not well tested for use in clinic making them more risky than non-biologics. O Because we must consider not only the benefit to the patients health, but also the cost of the medication and patient adherence, as non-biologic DMARDS are far more affordable. O The mechanisms of action are not fully understood for biologics but are fully understood for non-biologics making them safer. O All of the above are good reasons to prescribe a non-biologic DMARD first. >